Literature DB >> 23080321

Valuing QALY gains by applying a societal perspective.

Ana Bobinac1, N Job A van Exel, Frans F H Rutten, Werner B F Brouwer.   

Abstract

Interpreting the outcomes of cost utility analyses requires an appropriately defined threshold for costs per quality-adjusted life year (QALY). A common view is that the threshold should represent the (consumption) value a society attaches to a QALY. So far, individual valuations of personal health gains have mainly been studied rather than potentially relevant social values. In this study, we present the first direct empirical estimates of the willingness to pay for a QALY from a societal perspective. We used the contingent valuation approach, valuing QALYs under uncertainty and correcting for probability weighting. The estimates obtained in a representative sample of the Dutch population (n = 1004) range from €52,000 to €83,000, depending on the specification of the societal perspective. The scale sensitivity was weak, however.
Copyright © 2012 John Wiley & Sons, Ltd.

Keywords:  QALY; WTP; social perspective

Mesh:

Year:  2012        PMID: 23080321     DOI: 10.1002/hec.2879

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  21 in total

1.  Value of a QALY and VSI estimated with the chained approach.

Authors:  S Olofsson; U-G Gerdtham; L Hultkrantz; U Persson
Journal:  Eur J Health Econ       Date:  2019-06-06

2.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

3.  Economics of vaccines revisited.

Authors:  Maarten J Postma; Baudouin A Standaert
Journal:  Hum Vaccin Immunother       Date:  2013-01-30       Impact factor: 3.452

4.  Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity.

Authors:  Adriënne H Rotteveel; Mattijs S Lambooij; Nicolaas P A Zuithoff; Job van Exel; Karel G M Moons; G Ardine de Wit
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

5.  Cost-effectiveness of the PECARN rules in children with minor head trauma.

Authors:  Daniel K Nishijima; Zhuo Yang; Michael Urbich; James F Holmes; Marike Zwienenberg-Lee; Joy Melnikow; Nathan Kuppermann
Journal:  Ann Emerg Med       Date:  2014-11-12       Impact factor: 5.721

6.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

Review 7.  A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Authors:  Khachapon Nimdet; Nathorn Chaiyakunapruk; Kittaya Vichansavakul; Surachat Ngorsuraches
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

8.  Are all health gains equally important? An exploration of acceptable health as a reference point in health care priority setting.

Authors:  S Wouters; N J A van Exel; K I M Rohde; W B F Brouwer
Journal:  Health Qual Life Outcomes       Date:  2015-06-10       Impact factor: 3.186

9.  Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences.

Authors:  Jesus Martín-Fernández; Elena Polentinos-Castro; Ma Isabel del Cura-González; Gloria Ariza-Cardiel; Victor Abraira; Ana Isabel Gil-LaCruz; Sonia García-Pérez
Journal:  BMC Health Serv Res       Date:  2014-07-03       Impact factor: 2.655

10.  Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.

Authors:  Liesbet van de Wetering; Job van Exel; Ana Bobinac; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.